Join us for a fascinating conversation about the future of cancer research — and medicine — at our next Science Says on Tuesday, March 23. New technologies, genomic analysis, and massive data sets are transforming how we visualize the body, unlock the secrets of disease, and develop more precise diagnostic tools and treatments. Fred Hutch President and Director Dr. Tom Lynch will facilitate a conversation with three researchers who are leading us into the future.
We'll also save time for COVID Corner with Dr. Jim Kublin, executive director of the COVID-19 Prevention Network’s operations program, and answer as many of your questions as possible.
Thank you to our Science Says partner
LAIRD NORTON WEALTH MANAGEMENT
Dr. Thomas J. Lynch Jr., who will lead the conversation, is Fred Hutch president and holder of the Raisbeck Endowed Chair. He is a lung cancer physician and scientist who is respected worldwide for his pioneering role in precision medicine and his leadership in academic medicine and industry. He joined Fred Hutch one year ago — just weeks before COVID-19 shutdowns began — and has guided the organization’s response to the pandemic with urgency, compassion, and a commitment to sparking scientific solutions.
Dr. Rob Bradley is a computational biologist and biophysicist who uses sophisticated methods, new techniques like CRISPR knockouts, and statistical approaches to more rapidly detect molecular patterns underlying cancer and genetic diseases. The genetic links he discovers can become the targets of future therapies. Rob holds the McIlwain Family Endowed Chair in Data Science.
Dr. Melody Campbell is the inaugural director of our cryogenic electron microscopy (cryo-EM) facility. Cryo-EM is a groundbreaking technology that reveals the 3D form of proteins at the atomic level. Thanks to Melody’s expertise, our researchers can visualize and uncover how proteins work and cause disease, and how they can be targeted with vaccines or drugs to fight cancer, ward off infectious diseases, and correct genetic disorders.
Dr. Gavin Ha is a computational biologist who studies the role of genomic alterations in cancer. He and his team develop tools to detect vanishingly small amounts of tumor DNA in our blood. Oncologists hope to use these “liquid biopsies” to more easily diagnose cancer, monitor how patients’ tumors are responding to treatment, whether they’re developing drug resistance, and discover when a tumor has recurred.
Dr. Jim Kublin develops vaccines and treatments for life-threatening infectious diseases including COVID-19, HIV/AIDS, malaria, and tuberculosis. He is the executive director of the operations program for the COVID-19 Prevention Network, which manages large-scale testing of COVID-19 vaccines, and executive director of the HIV Vaccine Trials Network, both based at Fred Hutch.